Dr. Luc Marengère
Luc joined TVM Partners in 2012. He is responsible for TVM Partners overall investment strategy and global fund operations.
Luc has more than 25 years of venture capital experience. He is a key driver of the investment strategy for TVM LSI I and TVM LSI II Funds. He is a Director on the Boards of late-stage company Panthera Dental, Egg Medical, Kent Imaging, Emovi and Access Vascular as well as early-stage companies Vespina, Occellaris and Auricula. In addition, Luc was a Director on the Board of NASDAQ listed Acer Therapeutics (sold to Zevra Tharapeutics) and Colucid Pharma Inc. (sold to Eli Lilly for US$960M) as well as privately held Aurka Pharma Inc. (sold to Eli Lilly for US$575M; total value includes upfront plus CVRs) and Acanthas Pharma (sold to Eli Lilly for US$430M; total value includes upfront plus CVRs).
Luc brought a significant track record to TVM given his experience as a venture capitalist. Notable deals during Luc‘s tenure as Managing Partner at Toronto-based VG Partners where he founded the life science investment practice include Cytochroma Inc. (sold to Opko for US$400M); VisualSonics (sold to Sonosite for US$75M), CITA Neuropharma (sold to Vernalis Plc for US$85M) and Trillium Therapeutics (sold to Pfizer for US$2.2B). Prior to joining VG Partners, Luc focused on venture investments in the life science sector while at Montreal-based Caisse De Depot (CDP) as well as MDS Capital and MedTech Partners.
Prior to his venture capital career, he conducted commercially oriented research in the fields of immunology and oncology at Amgen. Luc holds a Ph.D. from University of Toronto (Medical Biophysics and Molecular Genetics), a Master’s degree from Queen’s University (Biochemistry) and a degree from University of Ottawa (Bachelor’s degree, Biochemistry, Magna Cum Laude).